Galaxy Therapeutics Achieves Enrollment Milestone in Critical SEAL IT IDE Trial Galaxy Therapeutics has successfully completed enrollment in its pivotal SEAL IT IDE trial, advancing neurointervention research for brain aneurysms.

Galaxy Therapeutics Achieves Enrollment Milestone in Critical SEAL IT IDE Trial #United_States #Milpitas #Galaxy_Therapeutics #brain_aneurysms #SEAL_IT